Vladimir Roudko

assistant professor, cancer immunologist, bioinformatics and cancer genomics

[Miriam Merad, MD, PhD @MiriamMerad]

Just heard the brilliant news that AlphaFold was awarded the lasker award- congratulation to Deemis Hassabis & team for a well deserved recognition https://t.co/e3HW9pz5mb

[Ron Alfa @Ronalfa]

Today we launch the next generation of AI oncology company with the support of great investors @hardimanjames @DCVC, @dreidco @ZettaVentures, 11.2, Intermountain Ventures, Epic Ventures, Catalio, North South Ventures, @viswacolluru @RecursionChris.

https://t.co/RqeAAwP91v

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

New generation of cancer-preventing vaccines enter early clinical trials for healthy people at high risk for disease #cancer #Immunotherapy
https://t.co/xizqgXMXP3

[antisense. @razoralign]

Storing and analyzing a genome on a blockchain https://t.co/vRVzOkOsdz

[Emily Bernstein Lab @bernstein_lab]

The @bernstein_lab is now on #Twitter! Follow us for lab updates and news on cancer epigenetics!!
🧬🔬

[Nature Reviews Drug Discovery @NatRevDrugDisc]

New updated analysis by the team at @CancerResearch in collaboration with @IQVIA_global of the PD1/PDL1 clinical trial landscape, including use of approved therapies in the clinic and a summary of new anti-PD1/PDL1 treatment modalities https://t.co/TwcJMVt8tK

[Vladimir Roudko @VRoudko]

Great news!

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

.@MountSinaiNYC has announced a transformative multimillion-dollar gift from Marc Lipschultz, who serves on Mount Sinai’s Boards of Trustees, and his wife, Jennifer, to the Precision Immunology Institute (PrIISM) at @IcahnMountSinai: https://t.co/roc4W6tDF0

[EMBL-EBI @emblebi]

The new @EMBL Programme has launched!

We're proud to be a part of @EMBL and we're looking forward to contributing our #bioinformatics expertise to this exciting new scientific programme that ushers in a new era in the life sciences.

[Vladimir Roudko @VRoudko]

Why sequence all eukaryotes? https://t.co/OuLFBRKnbC

[Science Magazine @ScienceMagazine]

A study evaluating effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the #Omicron variant indicates a third dose neutralizes Omicron at a similar order of magnitude as was observed after two doses of the vaccine against wild-type #SARSCoV2. https://t.co/pQbfIqkk64

[Vladimir Roudko @VRoudko]

Specialized ribosomes go immune! Role of protein translation in immunotherapy response and evasion gets first recognition.

[The Netherlands Cancer Institute @NKI_nl]

Group leaders Pia Kvistborg and William Faller received an ASPIRE award from the Mark Foundation. With it, they can dive into a brand new research field, chasing down ribosomes - the protein factories in the cells that may be sabotaging immunotherapy ➡️ https://t.co/Za37qPuQ31

[Britta Velten @brittavelten.bsky.social @BrittaVelten]

MEFISTO is out in Nature Methods - a framework for dimension reduction and integration of multi-modal omics data with temporal or spatial resolution. Paper at https://t.co/bdbfE0S9wL, highlights in the thread below. (1/7)

[dana_peer @dana_peer]

(1) Finally out, after one of the most painful and long reviews (with nitpicky reviews, see my last comment) is a method that I am extremely proud of and excited about. One of the best in my career: https://t.co/H31ZezbA1J

[Vladimir Roudko @VRoudko]

How does that even make any sense?

[Nature Neuroscience @NatureNeuro]

In this scenario, the cost of publication is covered by an Article Processing Charge (APC) paid at the time of publication. The APC for Nature Neuroscience in 2022 is €9,500/US $11,390/£8,290.

[Thomas Gardner @TJJardinero]

Excited to share my work from @DASLab_MSKCC lab out today in @nchembio where we develop CAR-T cells that produce small molecule drugs at the tumor site. This is an exciting step forward in the utilization of engineered cells for drug delivery! https://t.co/zuR7qs2JIr

[Science Magazine @ScienceMagazine]

Studying ~56 million T cells from 55 COVID patients, researchers in @SciImmunology offer a high-res picture of epitope reactivity and TCR usage in CD8 T cells specific for #SARSCoV2, some of which also react to “common cold” coronaviruses. https://t.co/nR21FGATD9

[GiulianaMagri @GMagri_Immuno]

Highly recommended review! 🤯😍😍👏
Germinal Centre Shutdown https://t.co/Rxsrc2Qvnp

[Science Magazine @ScienceMagazine]

A new method developed to reread a single polypeptide many times overcomes one of the biggest obstacles toward single-molecule proteomics.

Read more in a new #SciencePerspective: https://t.co/H5iI1ABOcD

[Cancer Research Institute @CancerResearch]

Findings from the KEYNOTE-522 trial show the addition of the immunotherapy agent pembrolizumab to chemotherapy before surgery decreased the recurrence by almost 40% in patients with early triple-negative breast cancer. #TNBC
https://t.co/ySLMHyC2pV

[Cell Reports @CellReports]

Protein modifications throughout the lung cancer proteome unravel the cancer-specific regulation of glycolysis https://t.co/EdMpag1K42